Project Grant R21TR005159
Award Date
7/3/25
Completion Date
6/30/27
Dollars Obligated
$408K
Federal Agency
National Center for Advancing Translational Sciences
Awardee
Nostopharma LLC (FKVPNPQK64H8)
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Washington, DC, USA
Similar Awards
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA program 93.846 "Arthritis, Musculoskeletal and Skin Diseases Research", provides $177,650 to conduct an observational study on the use of anti-IL1 therapy to reduce flare activity and heterotopic ossification in patients with Fibrodysplasia Ossificans Progressiva (FOP), a rare disease causing progressive and irreversible loss of mobility. The key...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the CFDA 93.350 National Center for Advancing Translational Sciences program, provides $489,500 to support research on developing a potential prophylactic intervention for Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM), a rare genetic disorder. The grant will fund studies to investigate how a small compound called Repsox may correct both the platelet defects and leukemic...
This National Science Foundation (NSF) Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,016,000 in funding to Nostopharma LLC to develop an innovative, sustained-release, and biodegradable drug delivery platform for localized treatment of post-traumatic injuries. The goal is to create a medication delivery system using anti-inflammatory nanoparticles embedded with a Hedgehog pathway antagonist, arsenic trioxide, to address unmet...
Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...
This federal Project Grant award, valued at $419,398, was provided by the National Center for Advancing Translational Sciences (NCATS) under the CFDA Program 93.350 to accelerate the translation of oligonucleotide therapeutics by enhancing delivery. The project aims to develop a small molecule solution to improve the delivery of systemically administered oligonucleotide therapeutics to extrahepatic tissues, a critical unmet need that has limited the broad clinical translation of these...
This $110,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 supports research by Greenstone Biosciences, Inc. to develop advanced drug discovery and development technologies for rare genetic disorders. The project aims to leverage induced pluripotent stem cell (iPSC) technology and artificial intelligence/machine learning (AI/ML) to accelerate and streamline the drug discovery process for myotonic dystrophy type 1 (DM1), a rare and...
This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $350,000 to Adiutrix Therapeutics LLC to develop a novel anti-fibrotic compound platform to identify and develop first-in-class therapeutics targeting collagen prolyl-4 hydroxylase (C-P4H) activity. The goal is to treat tissue remodeling and fibrosis in underserved diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma skin fibrosis, kidney fibrosis, and intestinal fibrosis...
This $589,255 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop small RNA targeting approaches, such as microRNA and siRNA, to advance treatments for heterotopic ossification (HO). HO is a condition involving pathologic bone formation in soft tissues that can occur following orthopedic surgeries or injuries. The award will fund the...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, aims to elucidate the role of TGF-beta signaling in craniofacial fibrous dysplasia (CFD), a debilitating skeletal disease. With total funding of $306,600 awarded on September 24, 2024, the project will investigate the mechanisms driving TGF-beta signaling in response to constitutive activation of G-protein coupled receptor...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $395,537 to Brigham & Women's Hospital Inc. to develop and validate CRISPR-based genome editing strategies to correct genetic mutations in the CLCN7 gene that cause osteopetrosis, a rare and debilitating skeletal disorder. The project aims to optimize genome editing techniques in...